Metabolic & Weight-Loss Research · Investigational Small Molecule
Bioglutide (NA-931)
An investigational orally active quadruple receptor agonist (IGF-1/GLP-1/GIP/glucagon) studied in weight-loss (obesity) research. A small molecule, not a peptide.
Bioglutide is the name used for NA-931, an investigational compound developed by Biomed Industries, Inc. It is described as a first-in-class quadruple receptor agonist, engineered to activate the IGF-1, GLP-1, GIP and glucagon receptors simultaneously — one receptor more than the triple agonists such as retatrutide that currently define the frontier of metabolic research.
What distinguishes NA-931 mechanically is not the receptor count but the route of administration. It is orally active. At roughly 500 daltons it is a cyclic small molecule derived from an IGF-1 metabolite — not a linear peptide. For comparison, semaglutide is approximately 4,114 daltons and tirzepatide approximately 4,810, and both require injection. NA-931’s small size and cyclic architecture are what allow it to resist gastrointestinal proteases and be absorbed from a once-daily oral capsule.
That distinction matters for anyone encountering this compound alongside research peptides: NA-931 is not a peptide, and it is not a compound we carry. Its molecular formula has not been publicly disclosed and no CAS number is published. Independent HPLC and mass-spectrometry verification requires a known reference standard, and none exists in the public domain. We publish a batch-matched Certificate of Analysis for every compound we sell, and we will not list a compound whose identity we cannot ask a third-party laboratory to confirm. Material offered elsewhere under this name cannot presently be verified against the compound described in the trial literature below.
All information here reflects published trial and preclinical research and is provided for educational, research-use-only purposes. NA-931 is an investigational compound in clinical development; it is not an approved drug and is not for human consumption.
Research areas
Quadruple-Receptor Mechanism
Engineered to co-activate IGF-1, GLP-1, GIP and glucagon receptors, adding an IGF-1 component to the incretin mechanisms studied in dual and triple agonists.
Oral Bioavailability
The defining feature and the reason for the research attention: a once-daily oral capsule rather than a subcutaneous injection, enabled by a structure that resists gastrointestinal proteases.
Small Molecule, Not a Peptide
At roughly 500 Da it is an order of magnitude smaller than semaglutide (~4,114 Da) or tirzepatide (~4,810 Da), and is structurally a cyclic glycine-proline analog rather than an amino-acid chain.
Lean-Mass Preservation
A recurring theme in the reported trial data and the basis on which the compound is compared with injectable incretin agonists in the research literature.
Recent research findings
- 2025Phase 2 results reported by the developer at ENDO 2025 and ADA 2025: a 13-week randomized, double-blind, placebo-controlled study in 125 adults, with mean weight reduction of up to 13.8% at 150 mg daily and no muscle loss observed. These figures are company-reported and await independent peer-reviewed publication.
- 2025Phase 1 clinical trial results published in Endocrine Practice, characterizing the quadruple-receptor profile and early tolerability.
- 2024Phase 2 trial registered on ClinicalTrials.gov as NCT06564753.
Published Research & Citations
The research summarized above is drawn from published, peer-reviewed studies. Explore the 5 sources below — links open the abstract or, where marked, the full free article on the U.S. National Library of Medicine (PubMed / PMC).
- 143-OR: NA-931, a Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist Reduces Body Weight without Muscle Loss. Diabetes (American Diabetes Association), 2025. ADA conference abstract reporting body-weight reduction without accompanying lean-mass loss.
- Phase 1 Clinical Trials Results of NA-931, a Novel Quadruple IGF-1, GLP-1, GIP, and Glucagon Receptor Agonist for the Treatment of Obesity. Endocrine Practice, 2025. Phase 1 results characterizing the receptor profile and early safety data.
- SAT-713: Phase 2 Clinical Trials of NA-931 to Study Subjects Who Are Obese With At Least One Weight-Related Comorbid Condition. Journal of the Endocrine Society, 2025. ENDO 2025 abstract describing the Phase 2 design and study population.
- NA-931 Phase 2 trial record, NCT06564753. ClinicalTrials.gov. Primary trial-registry entry for the Phase 2 obesity study.
- Biomed Industries Unveils Promising Phase 2 Results of NA-931, the First Oral Quadruple Agonist for Obesity at ENDO 2025. Biomed Industries, 2025. Developer announcement and the source of the reported efficacy figures. Company-reported, not independently peer-reviewed.